Drug intelligence / Profile preview

TO-O-1001

Development stage: Phase 2
Lead developer: Theratocular Biotek
Modality: Small Molecules
Administration: Ophthalmic

Overview

TO-O-1001 (formerly known as MG-O-1001) is a patented, new-generation Rho kinase (ROCK) inhibitor developed as an ophthalmic solution for the treatment of primary open-angle glaucoma and ocular hypertension. Its mechanism of action involves dual targeting that leads to relaxation of trabecular meshwork cells and the inner walls of Schlemm’s canal, thereby increasing aqueous humor outflow and lowering intraocular pressure. The drug is being developed and manufactured by Theratocular Biotek and has reached Phase I/II clinical trials for these indications.

Targets

ROCK2 (Rho-associated coiled-coil containing protein kinase 2)ROCK1 (Rho-associated coiled-coil containing protein kinase 1)MYLK4 (Myosin light chain kinase 4)

Beyond the preview

Go deeper on TO-O-1001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TO-O-1001.

Explore the full profile